Lyell Immunopharma (NASDAQ:LYEL) PT Lowered to $6.00

Lyell Immunopharma (NASDAQ:LYEL) had its target price cut by Bank of America from $9.00 to $6.00 in a research report report published on Thursday, Benzinga reports. They currently have a buy rating on the stock.

Separately, HC Wainwright restated a neutral rating and set a $1.00 price objective (down from $6.00) on shares of Lyell Immunopharma in a research note on Thursday.

Lyell Immunopharma Trading Up 5.1 %

Shares of NASDAQ:LYEL opened at $1.45 on Thursday. The firm’s 50 day moving average is $2.39 and its two-hundred day moving average is $2.24. The firm has a market capitalization of $369.66 million, a P/E ratio of -1.61 and a beta of -0.40. Lyell Immunopharma has a 52 week low of $1.18 and a 52 week high of $3.41.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Monday, May 6th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.04). Lyell Immunopharma had a negative net margin of 335,794.09% and a negative return on equity of 33.92%. Analysts predict that Lyell Immunopharma will post -0.85 EPS for the current year.

Institutional Investors Weigh In On Lyell Immunopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. WuXi AppTec Co. Ltd. bought a new position in Lyell Immunopharma during the 4th quarter valued at $15,871,000. Price T Rowe Associates Inc. MD grew its holdings in Lyell Immunopharma by 1.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,731,477 shares of the company’s stock worth $15,013,000 after acquiring an additional 92,594 shares during the period. Opaleye Management Inc. bought a new stake in Lyell Immunopharma in the first quarter worth about $7,482,000. Invenomic Capital Management LP lifted its holdings in Lyell Immunopharma by 16.8% in the 1st quarter. Invenomic Capital Management LP now owns 871,525 shares of the company’s stock valued at $1,944,000 after acquiring an additional 125,110 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Lyell Immunopharma by 1,052.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 225,506 shares of the company’s stock worth $437,000 after purchasing an additional 205,942 shares during the last quarter. Institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.